Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q2 FY24 results · Jul–Sep 2023
Gufic Biosciences reported revenue from operations of ₹214.87 crore and net profit of ₹23.21 crore for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 214.87 | — | — | — | — |
| Other income | 0.33 | — | — | — | — |
| Total income | 215.21 | — | — | — | — |
| Profit before tax | 30.95 | — | — | — | — |
| Net profit for the period | 23.21 | — | — | — | — |
| EPS, basic (₹) | 2.39 | — | — | — | — |
| Net margin (%) | 10.8 | — | — |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 214.87 | 174.84 | +22.9% | 195.02 | +10.2% |
| Other income | 0.33 | 0.82 | −59.1% | 0.88 | −62.1% |
| Total income | 215.21 | 175.65 | +22.5% | 195.90 | +9.9% |
| Profit before tax | 30.95 | 27.26 | +13.5% | 28.05 | +10.3% |
| Net profit for the period | 23.21 | 20.21 | +14.8% | 20.62 | +12.5% |
| EPS, basic (₹) | 2.39 | 2.09 | +14.4% | 2.13 | +12.2% |
| Net margin (%) | 10.8 | 11.6 | 10.6 |
Consolidated
- Filed with BSE
- 22 Nov 2023, 18:05 IST
- Board meeting
- 09 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 Nov 2023, 18:05 IST
- Board meeting
- 09 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE